Global Immunosuppressant Market Expected to Reach $42,511 Million by 2026

According to a new report published by Allied Market Research, titled, "Immunosuppressant Market by Drug Class, Indication, And Distribution Channels: Global opportunity Analysis and Industry Forecast, 2019–2026," the global immunosuppressant market size is expected to reach $42,511.37 million by 2026, registering a CAGR of 14.7% from 2019 to 2026, in terms of value. 

The global immunosuppressants market size was valued at $13,890 million in 2018 and is expected to reach $42,511 million by 2026, registering a CAGR of 14.7% from 2019 to 2026. Immunosuppressants are the drugs that are administered to minimize the chances of organ rejection after transplantation. For almost every individual who receives an organ transplant, immunosuppressants are a must to be taken. This is because immune system reacts to transplanted organs as foreign objects and develops an immune response against it, thereby, destroying the organ and at the same time affect other body parts as well. These drugs prevent hyper immune response of a patient’s body. These drugs are also widely used by patients suffering from auto-immune disorders such as Chron’s disease, irritable bowel disease, and arthritis.

Significant increase in the incidence of autoimmune disorders including arthritis and multiple sclerosis and rise in adoption of organ donation among individuals are the major factors that drive the immunosuppressant market growth. In addition, surge in government initiatives towards developing programmes for raising awareness related o organ transplantation propels the market growth. For instance, according to European National Health Service (NHS) in 2018, the U.K. government announced the introduction of new plans to change the law for organ and tissue donation to address urgent unmet need for organs within Indian-origin communities in the country. However, high cost of immunosuppressant drugs and side effects associated with them such as diarrhoea, higher susceptibility to infection, nausea, and vomiting are expected to hamper the growth of immunosuppressants market. On the contrary, the increase in use of tissue engineering for generation of implants provides growth opportunities to the immunosuppressant market trends. In addition, rise in disposable income in developing economies and surge in awareness among individuals toward organ donation is anticipated to create lucrative opportunities in the near future.

By drug class, the calcineurin inhibitors segment accounted for majority of the immunosuppressants market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the fact that it is the most used immunosuppressant drug used after organ transplantation to suppress hyper immune response. The most widely prescribed calcineurin inhibitors drugs include cyclosporine and tacrolimus. This segment is also anticipated to be the fastest growing drug class segment during the forecast period. 

By indication, the auto-immune disorder segment dominated the immunosuppressants market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the surge incidence of auto immune disorders across the globe. For instance, according to national institute of environmental health sciences (NIH), autoimmune diseases are among the most prevalent diseases in the U.S., affecting more than 23.5 million Americans. 

Key Findings of the Study:

• By drug class, the calcineurin inhibitors segment accounted for the highest market share of 35% in 2018 and is anticipated to grow at the fastest rate during the forecast period.
• By region, North America was the major shareholder and accounted for the highest share of 42% in 2018. 
• By indication, auto-immune disorder segment is expected to grow at a CAGR of 13.6% during the forecast period.
• By distribution channel, the hospital pharmacy segment dominated the market in 2018 and is anticipated to maintain its dominance during the forecast period.

Comprehensive competitive analysis and profiles of major market players such as Astellas Pharma, Inc., Bristol Myers Squibb, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Mylan Laboratories Inc., Novartis AG, Pfizer, Inc., Sanofi S.A. are provided in this report.